Achaogen Adds Janet Dorling As Chief Commercial Officer
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the addition of Ms. Janet Dorling as Chief Commercial Officer effective today. Ms. Dorling will report to Blake Wise, Achaogen’s President and Chief Operating Officer.
“We are very pleased to welcome Janet to the Achaogen team at this pivotal time, as we pursue regulatory approval of our lead product candidate, plazomicin, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae,” said Mr. Wise. “Janet is a highly effective commercial strategist with proven experience in driving global commercial success, including hands-on experience leading a large hospital-based products business in the U.S. With her proven ability to build and lead cross-functional teams, Janet’s appointment to this role fortifies our management team and underscores Achaogen’s commitment to commercialize new treatment options for serious MDR gram-negative infections.”
Ms. Dorling brings to Achaogen more than 14 years of experience in commercial sales and marketing of pharmaceutical products. Most recently, Ms. Dorling was the Vice President of Global Product Strategy, Breast Cancer at Roche/Genentech. In this role, Ms. Dorling was responsible for developing and implementing global commercialization and lifecycle strategies for the Breast Cancer Franchise. Previously, as Vice President of the Lytics Franchise, Ms. Dorling led hospital-focused Sales and Marketing teams that delivered double-digit revenue growth to achieve over one billion dollars in revenue in the acute care setting. Ms. Dorling has also led the Market Analysis and Strategy group at Genentech with portfolio-wide responsibility.
Ms. Dorling has a Bachelor of Arts in Molecular and Cellular Biology from the University of California at Berkeley, a Master’s in Science in Pharmacology and Cancer Biology from Duke University, and a Master’s in Business Administration from the Haas School of Business at the University of California at Berkeley.
“The CDC has characterized carbapenem-resistant Enterobacteriaceae as ‘nightmare bacteria’ and an immediate public health threat and, unfortunately, patients with serious MDR gram-negative infections have limited therapeutic options,” said Ms. Dorling. “I look forward to joining the committed and passionate team at Achaogen to deliver on the Company’s commercial objectives for plazomicin and to contribute to advancing an exciting pipeline.”
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
“We are very pleased to welcome Janet to the Achaogen team at this pivotal time, as we pursue regulatory approval of our lead product candidate, plazomicin, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae,” said Mr. Wise. “Janet is a highly effective commercial strategist with proven experience in driving global commercial success, including hands-on experience leading a large hospital-based products business in the U.S. With her proven ability to build and lead cross-functional teams, Janet’s appointment to this role fortifies our management team and underscores Achaogen’s commitment to commercialize new treatment options for serious MDR gram-negative infections.”
Ms. Dorling brings to Achaogen more than 14 years of experience in commercial sales and marketing of pharmaceutical products. Most recently, Ms. Dorling was the Vice President of Global Product Strategy, Breast Cancer at Roche/Genentech. In this role, Ms. Dorling was responsible for developing and implementing global commercialization and lifecycle strategies for the Breast Cancer Franchise. Previously, as Vice President of the Lytics Franchise, Ms. Dorling led hospital-focused Sales and Marketing teams that delivered double-digit revenue growth to achieve over one billion dollars in revenue in the acute care setting. Ms. Dorling has also led the Market Analysis and Strategy group at Genentech with portfolio-wide responsibility.
Ms. Dorling has a Bachelor of Arts in Molecular and Cellular Biology from the University of California at Berkeley, a Master’s in Science in Pharmacology and Cancer Biology from Duke University, and a Master’s in Business Administration from the Haas School of Business at the University of California at Berkeley.
“The CDC has characterized carbapenem-resistant Enterobacteriaceae as ‘nightmare bacteria’ and an immediate public health threat and, unfortunately, patients with serious MDR gram-negative infections have limited therapeutic options,” said Ms. Dorling. “I look forward to joining the committed and passionate team at Achaogen to deliver on the Company’s commercial objectives for plazomicin and to contribute to advancing an exciting pipeline.”
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.